Podcast Episodes
Back to SearchThe Allogeneic Future with Poseida's Kristin Yarema, Ph.D.
We love to hear from our listeners. Send us a message.
Kristin Yarema, Ph.D. thinks the progress of CAR T therapeutics is allogeneic. In fact, she sa…
1 year, 8 months ago
Expanding The Proteome with ProFound's John Lepore, M.D.
We love to hear from our listeners. Send us a message.
Flagship Pioneering’s ProFound Therapeutics is on to something, and it could be something big.…
1 year, 8 months ago
From The Bench To The Boardroom with ImmunityBio's Enrique Diloné
We love to hear from our listeners. Send us a message.
While organic chemistry lectures caused many of his peers at NYU to wring their hands, gnash t…
1 year, 8 months ago
First AI Antibody In Humans with Aulos' Aron Knickerbocker
We love to hear from our listeners. Send us a message.
Data drives decision-making at Aulos Bioscience. It's also driven the career trajectory of its…
1 year, 9 months ago
Drug Delivery Differentiators with Syncromune's Eamonn Hobbs
We love to hear from our listeners. Send us a message.
Syncromune's Sync-T solid tumor therapeutic platform is, in a word, complex. The company's thr…
1 year, 9 months ago
Topical Ocular Biologics with Claris Bio's Clarke Atwell
We love to hear from our listeners. Send us a message.
Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil …
1 year, 9 months ago
C&G Regulatory Guidance with Lineage Therapeutics' Brian Culley
We love to hear from our listeners. Send us a message.
When we last caught up with Brian Culley, CEO at Lineage Cell Therapeutics, it was January, 20…
1 year, 9 months ago
True DEI Value in Biopharma with Arcellx's Rami Elghandour
We love to hear from our listeners. Send us a message.
The cell therapy company Arcellx has, by any and every measure, been outperforming its peers. …
1 year, 10 months ago
Mission-Driven Dementia Funding with DDF's Jonathan Behr
We love to hear from our listeners. Send us a message.
If there's anyone qualified to analyze an early-stage therapeutic technology and place bets wi…
1 year, 10 months ago
ADCs Ignited with Daiichi Sankyo Inc.'s Ken Keller
We love to hear from our listeners. Send us a message.
Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics s…
1 year, 10 months ago